Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

3.9K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.9K
The Tumor Microenvironment02:17

The Tumor Microenvironment

8.1K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
8.1K
The Tumor Microenvironment02:17

The Tumor Microenvironment

3.0K
3.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Tumor Progression02:07

Tumor Progression

7.8K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.8K
Tumor Progression02:07

Tumor Progression

3.5K
3.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Emotional and Behavioral Effects of an Online Self-Reflective Meditation Program in Youth With ADHD: A Randomized Clinical Trial.

Clinical child psychology and psychiatry·2026
Same author

Platelet extravasation in the microvasculature: an under-appreciated role for platelets.

Frontiers in immunology·2026
Same author

LATS1/2-CD38 Metabolic Rewiring Links Senescence to Intraplaque Thrombosis.

Circulation research·2026
Same author

Platelets: the next-generation ovarian cancer biomarker?

Trends in cancer·2026
Same author

B cell depletion promotes melanoma tumor growth in a CD4+ T cell-dependent manner.

Journal of immunology (Baltimore, Md. : 1950)·2026
Same author

Long-term outcome and management of complement-mediated thrombotic microangiopathy/aHUS.

Hematology. American Society of Hematology. Education Program·2025

Related Experiment Video

Updated: Mar 24, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K

Platelets induce VISTA expression and modulate the ovarian tumor microenvironment.

Hani Lee1, Brianne Sager1, Anil Sood2

  • 1The Section of Benign Hematology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Platelets
|March 17, 2026
PubMed
Summary

Platelets boost VISTA expression in ovarian cancer, creating an immunosuppressive tumor microenvironment (TME). Targeting this platelet-VISTA interaction may improve antitumor immunity.

Keywords:
Immune checkpointneutrophilsovarian cancerplatelet

More Related Videos

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.1K
A Proximal Culture Method to Study Paracrine Signaling Between Cells
08:17

A Proximal Culture Method to Study Paracrine Signaling Between Cells

Published on: August 28, 2018

10.1K

Related Experiment Videos

Last Updated: Mar 24, 2026

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence
08:55

Murine Model for Non-invasive Imaging to Detect and Monitor Ovarian Cancer Recurrence

Published on: November 2, 2014

12.9K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1
07:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

3.1K
A Proximal Culture Method to Study Paracrine Signaling Between Cells
08:17

A Proximal Culture Method to Study Paracrine Signaling Between Cells

Published on: August 28, 2018

10.1K

Area of Science:

  • Immunology
  • Oncology
  • Hematology

Background:

  • Immune checkpoint regulators like V-domain Ig suppressor of T cell activation (VISTA) are crucial in tumor immune evasion.
  • VISTA is highly expressed in ovarian cancer, exceeding Programmed Death-Ligand 1 (PD-L1) levels.
  • The role of platelets in regulating VISTA in ovarian cancer remains underexplored.

Purpose of the Study:

  • To investigate the role of platelets in regulating VISTA expression in ovarian cancer.
  • To determine the impact of platelet-mediated VISTA upregulation on the tumor microenvironment (TME).

Main Methods:

  • Utilized in vitro and in vivo models of ovarian cancer.
  • Assessed VISTA expression in myeloid and tumor cells.
  • Correlated VISTA levels with platelet counts and clinical outcomes.

Main Results:

  • Platelets were found to upregulate VISTA expression in both myeloid and tumor cells.
  • This upregulation promotes an immunosuppressive TME in ovarian cancer.
  • Elevated VISTA levels correlated with increased platelet counts and poorer patient outcomes.

Conclusions:

  • Platelets significantly contribute to VISTA upregulation in ovarian cancer.
  • Platelet-mediated VISTA induction creates an immunosuppressive TME.
  • Targeting the platelet-VISTA axis presents a potential therapeutic strategy for ovarian cancer.